EGFR and neoplasm: Among mechanisms of therapy resistance to EGFR inhibitors are: PTEN (phosphatase and tensin homolog) alterations, deregulated PI3K (phosphatidylinositol 3-kinase) pathway [29,30], compensatory signaling pathways, tumor heterogeneity and ineffective BBB penetration [31].